The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Is the mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin (ddTC) than to conventional taxane and carboplatin chemotherapy (TC) in high grade serous ovarian carcinoma? A survey of Japanese Gynecology Oncology Group study (JGOG3016A1).
 
Ryusuke Murakami
No Relationships to Disclose
 
Noriomi Matsumura
Research Funding - Daiichi Sankyo (Inst)
 
Hiroshi Tanabe
No Relationships to Disclose
 
Hirofumi Michimae
No Relationships to Disclose
 
Mayu Yunokawa
No Relationships to Disclose
 
Haruko Iwase
No Relationships to Disclose
 
Motoi Sasagawa
No Relationships to Disclose
 
Toshiaki Nakamura
No Relationships to Disclose
 
Osamu Tokuyama
No Relationships to Disclose
 
Masashi Takano
No Relationships to Disclose
 
Toru Sugiyama
Honoraria - AstraZeneca; BMS Brazil; Chugai Pharma
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Ono Pharmaceutical
 
Takashi Sawasaki
No Relationships to Disclose
 
Seiji Isonishi
No Relationships to Disclose
 
Kazuhiro Takehara
Speakers' Bureau - AstraZeneca; AstraZeneca; Chugai Pharma; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Janssen; Janssen; Kyowa Hakko Kirin; Nippon Kayaku; Nippon Kayaku; Taiho Pharmaceutical
 
Hidekatsu Nakai
No Relationships to Disclose
 
Aikou Okamoto
No Relationships to Disclose
 
Masaki Mandai
No Relationships to Disclose
 
Ikuo Konishi
No Relationships to Disclose